EGRX Eagle Pharmaceuticals Inc

Price (delayed)

$47.84

Market cap

$627.15M

P/E Ratio

44.71

Dividend/share

N/A

EPS

$1.07

Enterprise value

$553.18M

Highlights
Eagle Pharmaceuticals's debt has shrunk by 79% YoY and by 6% QoQ
The EPS has grown by 20% from the previous quarter
Eagle Pharmaceuticals's quick ratio has soared by 103% YoY but it has decreased by 11% from the previous quarter
Eagle Pharmaceuticals's gross margin has increased by 3.4% YoY but it has decreased by 3% from the previous quarter
Eagle Pharmaceuticals's gross profit has decreased by 5% QoQ
The company's revenue fell by 4.7% YoY and by 2.5% QoQ

Key stats

What are the main financial stats of EGRX
Market
Shares outstanding
13.11M
Market cap
$627.15M
Enterprise value
$553.18M
Valuations
Price to earnings (P/E)
44.71
Price to book (P/B)
3.31
Price to sales (P/S)
3.42
EV/EBIT
18.99
EV/EBITDA
16.31
EV/Sales
3.02
Earnings
Revenue
$183.03M
EBIT
$29.14M
EBITDA
$33.91M
Free cash flow
$56.16M
Per share
EPS
$1.07
Free cash flow per share
$4.3
Book value per share
$14.46
Revenue per share
$14
TBVPS
$15.92
Balance sheet
Total assets
$259.97M
Total liabilities
$68.89M
Debt
$31.25M
Equity
$191.08M
Working capital
$122.01M
Liquidity
Debt to equity
0.16
Current ratio
3.91
Quick ratio
3.58
Net debt/EBITDA
-2.18
Margins
EBITDA margin
18.5%
Gross margin
73.5%
Net margin
7.9%
Operating margin
13.7%
Efficiency
Return on assets
5.7%
Return on equity
7.9%
Return on invested capital
31.6%
Return on capital employed
13.4%
Return on sales
15.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EGRX stock price

How has the Eagle Pharmaceuticals stock price performed over time
Intraday
0.38%
1 week
0.53%
1 month
16.4%
1 year
-2.13%
YTD
2.73%
QTD
11.78%

Financial performance

How have Eagle Pharmaceuticals's revenue and profit performed over time
Revenue
$183.03M
Gross profit
$134.51M
Operating income
$25.15M
Net income
$14.44M
Gross margin
73.5%
Net margin
7.9%
The operating margin has soared by 93% year-on-year but it has declined by 22% since the previous quarter
Eagle Pharmaceuticals's operating income has surged by 84% YoY but it has decreased by 24% QoQ
Eagle Pharmaceuticals's net margin has increased by 23% QoQ
The net income has increased by 20% since the previous quarter

Growth

What is Eagle Pharmaceuticals's growth rate over time

Valuation

What is Eagle Pharmaceuticals stock price valuation
P/E
44.71
P/B
3.31
P/S
3.42
EV/EBIT
18.99
EV/EBITDA
16.31
EV/Sales
3.02
The EPS has grown by 20% from the previous quarter
EGRX's P/B is 35% below its 5-year quarterly average of 5.1
The company's equity rose by 5% YoY and by 2.7% QoQ
EGRX's price to sales (P/S) is 19% lower than its 5-year quarterly average of 4.2 but 3.6% higher than its last 4 quarters average of 3.3
The company's revenue fell by 4.7% YoY and by 2.5% QoQ

Efficiency

How efficient is Eagle Pharmaceuticals business performance
EGRX's return on invested capital has surged by 190% year-on-year and by 20% since the previous quarter
Eagle Pharmaceuticals's ROA has increased by 33% from the previous quarter
Eagle Pharmaceuticals's return on equity has increased by 20% QoQ
The ROS has grown by 19% from the previous quarter

Dividends

What is EGRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EGRX.

Financial health

How did Eagle Pharmaceuticals financials performed over time
EGRX's current ratio has soared by 107% YoY but it is down by 10% QoQ
Eagle Pharmaceuticals's quick ratio has soared by 103% YoY but it has decreased by 11% from the previous quarter
Eagle Pharmaceuticals's debt is 84% lower than its equity
Eagle Pharmaceuticals's debt to equity has plunged by 80% YoY and by 11% from the previous quarter
Eagle Pharmaceuticals's debt has shrunk by 79% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.